寡转移性去势敏感前列腺癌患者接受[177Lu]Lu-PSMA-617放射配体治疗联合立体定向体部放疗的病灶剂量学研究
单中心前瞻性先导临床试验纳入6例患者共9个PSMA阳性寡转移灶,接受2周期[177Lu]Lu-PSMA-617放射配体治疗后行立体定向体部放疗。病灶剂量学可行,联合治疗未出现3级及以上毒性,RPT两周期对RPT与SBRT最大BED贡献约40%。
要点
- 6例患者9个PSMA阳性寡转移灶完成[177Lu]Lu-PSMA-617两周期联合SBRT,无并发症及3级及以上毒性。
- 第一周期RPT病灶吸收剂量中位27.7 Gy(范围8.3-58.2 Gy),SBRT病灶吸收剂量中位28.1 Gy(范围26.7-28.8 Gy)。
- RPT与SBRT的病灶BED中位159 Gy(范围124-219 Gy),两周期RPT对最大BED贡献约40%。
核心结论
- 在寡转移性去势敏感前列腺癌患者中,[177Lu]Lu-PSMA-617放射配体治疗后行SBRT的病灶剂量学是可行的。
- 联合RPT与SBRT可能提供一种高效方法,在向寡转移病灶递送有意义剂量的同时处理潜在微小病灶储库并限制正常组织剂量暴露。
研究设计与样本
- 单中心前瞻性先导临床试验,纳入6例患者共9个PSMA阳性寡转移灶。
- 患者接受2周期[177Lu]Lu-PSMA-617放射配体治疗,第一周期静脉输注7.46 ± 0.15 GBq后于3.2 ± 0.5、23.9 ± 0.4和87.4 ± 12.0 h行SPECT/CT。
- 基于体素的剂量学采用校准因子11.7 counts per second/MBq及本院体模实验得出的恢复系数。
- 病灶在基线PSMA PET/CT上以50% SUVmax分割;第二周期[177Lu]Lu-PSMA-617(44 ± 3 d;7.50 ± 0.10 GBq)及中期PSMA PET/CT后,对所有PSMA高摄取寡转移灶行SBRT(27 Gy分3次),随后行post-PSMA PET/CT。
- RPT与SBRT体素剂量图按α/β = 3 Gy、修复半衰期1.5 h缩放以计算生物有效剂量(BED)。
主要发现
- 所有患者完成联合治疗且无并发症,未观察到3级及以上毒性。
- PSMA PET测得病灶SUVmax中位数:基线16.8(四分位距11.6)、中期6.2(四分位距2.7)、post 2.9(四分位距1.4);PET衍生病灶体积0.4-1.7 cm3。
- 第一周期[177Lu]Lu-PSMA-617 RPT的病灶吸收剂量(ADRPT)中位27.7 Gy(范围8.3-58.2 Gy;对应3.7 Gy/GBq,范围1.1-7.7 Gy/GBq),SBRT病灶吸收剂量中位28.1 Gy(范围26.7-28.8 Gy)。
- 基线病灶PET SUVmax与SPECT SUVmax的Spearman秩相关系数ρ=0.90(P = 0.005),基线PET SUVmax与病灶ADRPT的ρ=0.74(P = 0.046),病灶ADRPT与PET SUVmax自基线至中期变化百分比的ρ=-0.81(P = 0.022)。
- RPT与SBRT的病灶BED中位159 Gy(范围124-219 Gy);RPT与SBRT的BED与PET SUVmax自基线至post变化百分比的ρ=-0.88(P = 0.007);两周期[177Lu]Lu-PSMA-617 RPT对RPT与SBRT最大BED贡献约40%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A single-institution prospective pilot clinical trial was performed to demonstrate the feasibility of combining [177Lu]Lu-PSMA-617 radiopharmaceutical therapy (RPT) with stereotactic body radiotherapy (SBRT) for the treatment of oligometastatic castration-sensitive prostate cancer. Methods: Six patients with 9 prostate-specific membrane antigen (PSMA)-positive oligometastases received 2 cycles of [177Lu]Lu-PSMA-617 RPT followed by SBRT. After the first intravenous infusion of [177Lu]Lu-PSMA-617 (7.46 ± 0.15 GBq), patients underwent SPECT/CT at 3.2 ± 0.5, 23.9 ± 0.4, and 87.4 ± 12.0 h. Voxel-based dosimetry was performed with calibration factors (11.7 counts per second/MBq) and recovery coefficients derived from in-house phantom experiments. Lesions were segmented on baseline PSMA PET/CT (50% SUVmax). After a second cycle of [177Lu]Lu-PSMA-617 (44 ± 3 d; 7.50 ± 0.10 GBq) and an interim PSMA PET/CT scan, SBRT (27 Gy in 3 fractions) was delivered to all PSMA-avid oligometastatic sites, followed by post-PSMA PET/CT. RPT and SBRT voxelwise dose maps were scaled (α/β = 3 Gy; repair half-time, 1.5 h) to calculate the biologically effective dose (BED). Results: All patients completed the combination therapy without complications. No grade 3+ toxicities were noted. The median of the lesion SUVmax as measured on PSMA PET was 16.8 (interquartile range [IQR], 11.6) (baseline), 6.2 (IQR, 2.7) (interim), and 2.9 (IQR, 1.4) (post). PET-derived lesion volumes were 0.4-1.7 cm3 The median lesion-absorbed dose (AD) from the first cycle of [177Lu]Lu-PSMA-617 RPT (ADRPT) was 27.7 Gy (range, 8.3-58.2 Gy; corresponding to 3.7 Gy/GBq, range, 1.1-7.7 Gy/GBq), whereas the median lesion AD from SBRT was 28.1 Gy (range, 26.7-28.8 Gy). Spearman rank correlation, ρ, was 0.90 between the baseline lesion PET SUVmax and SPECT SUVmax (P = 0.005), 0.74 (P = 0.046) between the baseline PET SUVmax and the lesion ADRPT, and -0.81 (P = 0.022) between the lesion ADRPT and the percent change in PET SUVmax (baseline to interim). The median for the lesion BED from RPT and SBRT was 159 Gy (range, 124-219 Gy). ρ between the BED from RPT and SBRT and the percent change in PET SUVmax (baseline to post) was -0.88 (P = 0.007). Two cycles of [177Lu]Lu-PSMA-617 RPT contributed approximately 40% to the maximum BED from RPT and SBRT. Conclusion: Lesional dosimetry in patients with oligometastatic castration-sensitive prostate cancer undergoing [177Lu]Lu-PSMA-617 RPT followed by SBRT is feasible. Combined RPT and SBRT may provide an efficient method to maximize the delivery of meaningful doses to oligometastatic disease while addressing potential microscopic disease reservoirs and limiting the dose exposure to normal tissues.
引用
- Grkovski M, O'Donoghue JA, Imber BS, et al. Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer. J Nucl Med. 2023. PMID: 37652541. doi:10.2967/jnumed.123.265763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。